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BACKGROUND: Interruption of the role of p53s as a tumour suppressor by MDM2 may be one of the mechanisms by which cancer cells
evade current therapy. Blocking the inhibition of wild-type p53 by MDM2 in cancer cells should reactivate p53’s tumour suppressor
functions and enhance current cancer treatments. MI-63 is a novel non-peptide small molecule that has shown strong binding affinity
(Ki¼3n M) for MDM2; however, its effects on paediatric cancer cells and the specific mechanism of tumour suppressor reactivation
have not been evaluated.
METHODS: Rhabdomyosarcoma (RMS), the most common childhood soft tissue sarcoma, expresses either wild-type or mutant p53
protein. We examined the inhibitory effects of MI-63 in embryonal RMS (ERMS) and alveolar RMS (ARMS) cell lines expressing wild-
type or mutated p53.
RESULTS: Treatment with MI-63 reduced cell viability by 13.4% and by o1%, respectively, at 72h in both RH36 and RH18 cell lines
expressing wild-type p53. In contrast, RH30 and RD2 cells expressing p53 mutants are resistant to MI-63 treatment. An increased
expression of p53, p21
WAF1, and Bax protein was observed after treatment with MI-63 in RMS cells with wild-type p53, and
apoptosis was confirmed by cleaved PARP and caspase-3 expression. However, RD2 and RH30 RMS cells, as well as human normal
skeletal muscle cells, showed a minimal increase in p53 signalling and no induction of cleaved PARP and caspase-3. MI-63 was
compared with Nutlin-3, a known MDM2 inhibitor, and was found to be more potent in the inhibition of cell proliferation/viability.
Further, synergy was observed when MI-63 was used in combination with doxorubicin.
CONCLUSION: These results indicate that MI-63 is a potent therapeutic agent for RMS cells expressing wild-type p53 protein.
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Rhabdomyosarcoma (RMS) is the most common paediatric
soft tissue sarcoma with a yearly incidence of approximately 4.6
cases per million (Ries and SEER Program (National Cancer
Institute (US)), 1999; Breneman et al, 2003). Although a highly
heterogeneous tumour, the most common histologic subtypes of
RMS are embryonal rhabdomyosarcoma (ERMS) and alveolar
rhabdomyosarcoma (ARMS) (Davicioni et al, 2006). IRS-III
outcome data indicate that, with multimodal therapy, cure rates
have improved to nearly 70%; however, survival of children with
aggressive subtypes (i.e., ARMS) or with metastatic disease
continues to be poor (Crist et al, 1995; Pappo et al, 1995; Taylor
et al, 2000; Breneman et al, 2003). Attempts to improve survival
have not been successful with different combinations of known
chemotherapeutic agents; thus, the need for novel therapies (Raney
et al, 2001).
The p53 protein regulates cell cycle, repairs DNA, and initiates
apoptosis (Ding et al, 2006). Thus, p53’s role as a tumour
suppressor is well known and studied. p53 is mutated in paediatric
malignancies in approximately 50% of cases; however, the
frequency of mutations differs among tumour types (Taylor
et al, 2000; Ding et al, 2006). The remaining tumours that
retain wild-type p53 develop alternative mechanisms that disrupt
normal function and lead to malignant proliferation (Tovar et al,
2006). Overexpression of MDM2, a regulator of p53 transcription,
leads to abnormal protein–protein interactions and inhibits p53
activity.
Stability of the p53–MDM2 interaction is necessary for cell-
cycle arrest and apoptosis. When the balance between MDM2 and
p53 is disrupted, MDM2 upregulation inhibits the function of p53
as a tumour suppressor (Chen et al, 1995; Taylor et al, 2000;
Takahashi et al, 2004; Tovar et al, 2006). Specifically, reports
identify approximately one-third of sarcomas with MDM2 over-
expression and thus, an interruption of p53 activity (Keleti et al,
1996; Taylor et al, 2000). RMS tumour cells with both mutated and
wild-type p53 have been identified (Keleti et al, 1996; Taylor et al,
2000). Although the frequency of wild-type p53 is unclear, RMS
tumours with wild-type p53, with or without MDM2 amplification, Received 28 May 2009; revised 29 June 2009; accepted 30 June 2009
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sare a good target for small-molecule inhibitors, potentially
allowing for reactivation of protein signalling.
MI-63, a novel, non-peptide small-molecule inhibitor, shows
promise as an inhibitor of the p53–MDM2 interaction in prostate
cancer cells with wild-type p53; however, it has not been tested in
paediatric sarcomas (Ding et al, 2006). Previously, non-peptide
small-molecule inhibitors of the p53–MDM2 interaction have
targeted three, well-described, hydrophobic residues (Phe19,
Trp23, and Leu26); however, the MI63 design includes a fourth
residue (Leu22) that has an important role in p53 binding to
MDM2 (Lin et al, 1994; Kussie et al, 1996; Ding et al, 2006).
Incorporating this residue, MI-63 now has a greater binding
affinity to MDM2, Ki value of 3nM, and high selectivity in blocking
p53–MDM2 interaction when compared with previously described
non-peptide inhibitors (Ding et al, 2006). MI-63 has been shown to
reactivate wild-type p53 function and decrease cancer cell
proliferation (Ding et al, 2006).
To investigate the effect of MI-63 on paediatric sarcomas,
specifically RMS, and the reactivation of p53 cell signalling, we
designed an in vitro study examining cancer cell proliferation
and presence of apoptosis after exposure to the inhibitor. ERMS
and ARMS cell lines with wild-type p53 were treated with
MI-63, and cell proliferation and levels of p53, p21
WAF1, Bax,
cleaved PARP, and cleaved caspase-3 protein were evaluated. On
the basis of MI-63 binding potential and data presented in adult
tumours, we expected a reactivation of the p53 signalling pathway
and subsequent RMS cell death.
In addition, our experiment evaluated the synergism between
the known cytotoxic agent, doxorubicin, and MI-63. Although
many chemotherapeutic agents have been used in an attempt to
treat RMS, toxicities and treatment failures provide motivation for
the discovery of new agents and combinations. Combined
chemotherapy allows the treatment of cancer cells through
different mechanisms, with goals of improving outcome and
minimising toxicity. Evidence of enhanced tumour suppression
would be encouraging, and may indicate an ability to achieve
similar or improved treatment outcomes with decreased toxicities.
MATERIALS AND METHODS
Human cancer cell lines
HCT-116 p53 þ/þ and HCT-116 p53  /  colon cancer cells were
kindly provided by Berg Volgelsten’s laboratory at the John
Hopkins University. Both colon cancer cell lines were cultured in
DMEM media with L-glutamine (Mediatech, Inc.; Herndon, VA,
USA) containing 10% FBS (Gibco; Grand Island, NY, USA) and 1%
by volume penicillin/streptomycin (Invitrogen Life Technologies;
Carlsbad, CA, USA). ERMS cell, RH36, and ARMS cells, RH18 and
RH30, were a gift from Peter Houghton at St. Judes Children’s
Research Hospital. The RD2 tumour cell line (ERMS) was a gift
from Brett Hall at The Ohio State University. All RMS cell lines
were cultured in RPMI-1640 media with L-glutamine (Mediatech,
Inc.) containing 10% FBS and 1% by volume penicillin/strepto-
mycin (Invitrogen Life Technologies). Human skeletal muscle
cells (HMSS) were purchased from Lonza Walkersville Inc
(Walkersville, MD, USA). Normal human cells were cultured in
SkBM-2 medium containing hEGF, Dexamethasone, L-glutamine,
FBS and Gentamicin/Amphotericin-B in pre-mixed aliquots as
per manufacturer’s instructions. All cell lines were cultured
until confluent and maintained in humidified incubators at 371C
and 5% CO2.
Small-molecule compound
The small-molecule inhibitor, MI-63, was provided by Dr
Shaomeng Wang’s laboratory at the University of Michigan
(Figure 1). MI-63 was dissolved in DMSO (ATCC; Manassas, VA,
USA) to a 10mM stock solution and stored at  201C.
MTT cell viability assay
Cell lines were plated at 7000 cells/well (100ml/well) into a 96-well
plate and incubated overnight. The medium was removed and
replaced with fresh DMEM or RPMI either by itself, with DMSO
(7ml dissolved in 10ml of DMEM or RPMI), or with MI-63
concentrations of 5mM or 10mM. Treated cells were incubated up to
72h. Each well was then incubated with Thiazolyl Blue Tetrazolium
Bromide (MTT; Sigma; St Louis, MO, USA) for 3h. Formazan
crystals were solubilised with a detergent containing 1:1 dilution
of N,N-demethylformamide (Sigma) and 20% SDS, wt/vol (Fisher
Scientific; Fair Lawn, NJ). Spectrophotometric absorbance of the
plate was recorded at 595nm using an EL808 Ultra Microplate
Reader (Bio-Tek Instruments, Inc; Winooski, VT, USA). Data were
collected using KC Junior software (Bio-Tek Instruments, Inc) and
exported to Microsoft Excel for analysis. Half-Maximal inhibitory
concentrations (IC50) were determined using Sigma Plot 9.0
software (Systat Software Inc., San Jose, CA, USA) with the
4-parameter logistic function standard curve analysis for dose
response.
Western blot analysis
Cell lines were plated in 10cm plates at a concentration of 400000
cells/plate and were allowed to adhere overnight. Cells were
incubated in DMEM, RPMI, or SkBM-2 medium (HMSS), with
growth factors as above, for 24h (RH18 cells were incubated for
48h). After treating with 5 and 10mM of MI-63, the cells were washed
with PBS and lysed in SDS lysis buffer (62.5mM Tris-HCL, 2% w/v
SDS, 10% glycerol, 50nM DTT, 0.02% w/v bromphenol blue).
Whole-cell lysates were boiled at 951C in water for 5min
and separated on 10% or 12% glycine-based SDS PAGE gels. After
electrophoresis, samples were transferred to a polyvinylidine
fluoride membrane (PVDF). The PVDF membrane was blocked in
5% milk in 1% Tween-20 in TBS (TBST) for an hour at room
temperature. The membrane was then incubated overnight with a
primary antibody at 4
1C in 2.5% milk in TBST. Thereafter, blots
were incubated for over an hour with a fluorescein-linked secondary
antibody, and then for 30min with an alkaline-phosphatase-linked
anti-fluorescein tertiary antibody. Protein bands were visualised
using an ECL chemiluminescent substrate and the Storm Scanner.
Primary antibodies for p53, p21
WAF1, MDM2, cleaved caspase-3,
cleaved PARP, GAPDH, and Bax were obtained from Cell Signaling
Technologies (Danvers, MA, USA). Secondary antibodies were
obtained from Jackson Immuno Research Laboratories (West
Grove, PA, USA) and the tertiary antibody was purchased from
Sigma-Aldrich Inc. (St Louis, MO, USA).
Determination of the half-life of p53
RH36 cells were treated with either DMSO or 5mM MI-63 and
incubated for 24h. The cells were then treated with 50mg/ml of
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Figure 1 Chemical structure of MI-63.
MI-63: Targeting MDM2 in rhabdomyosarcoma
JA Canner et al
775
British Journal of Cancer (2009) 101(5), 774–781 & 2009 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
scycloheximide (Sigma) and harvested at 0, 60, and 120min
as described above. Western blot analysis was carried out to
determine the levels of p53.
Determination of combinatorial effects
Doxorubicin and MI-63 synergy with regard to growth inhibition
were determined as set forth by Chou and Talalay, (1984). Briefly,
the log (fa/fu) was plotted against the concentration (D) for each
compound, alone or in combination, where fa is the fraction
affected and fu is the fraction unaffected (1-fa) of cells at each
concentration. Calcusyn software (Biosoft, Ferguson, MO, USA),
programmed in accordance with the methods described by Chou
(Chou and Talalay, 1984), was used to determine the combina-
tional index (CI) for each concentration of drug mixture used. A
value CI less than 1 represents synergism between doxorubicin and
MI-63. A value equal to/greater than 1 represents additive effects
and antagonistic effects, respectively.
RESULTS
MI-63 induces p53 and downstream cell signalling in
HCT-116 p53þ/þ
The colon cancer cell lines, HCT-116 p53þ/þ and p53 / , were
evaluated for p53 specificity. HCT-116 p53þ/þ cells incubated
with 5 and 10mM of MI-63 (Figure 1) had decreased cell
proliferation at days 2 (70.5%±9.21 and 62.7%±7.7, respectively)
and 3 (40.4%±7.57 and 34.2%±6.33, respectively) using MTT
assay (Figure 2A). Increases in p53, p21
WAF1, cleaved caspase-3,
and cleaved PARP proteins were found on western blot analysis. In
contrast, HCT-116 p53 /  cells incubated with 5 and 10mM of
MI-63 showed a minimal change in cellular proliferation on
day 2 (95.1%±3.91 and 96.1%±5.56, respectively) and day 3
(113.6%±7.66 and 99.6%±7.07, respectively). Western blot
analysis showed no evidence of p53, p21
WAF1, or cleaved
caspase-3 induction, and cleaved PARP was not increased. GAPDH
demonstrated equal protein loading (Figure 2B).
MI-63 reactivates p53 protein and induces apoptosis in
RMS
An ERMS cell line with wild-type p53, RH36, incubated with 5 and
10mM of MI-63 for 1–3 days, was evaluated. MTT assay showed
decreased cell proliferation/viability across 3 days of exposure with
5 and 10mM of MI-63 (48.7%±5.41 and 48.7%±11.02 on day 1;
35.9%±26.56 and 35.6%±28.47 on day 2; 13.4%±16.11 and
9.8%±15.30 on day3) (Figure 3A). Similarly, a histologic ARMS
cell line with wild-type p53, RH18, was incubated with 5 and 10mM
of MI-63 for the same duration. MTT assay identified decreased
cell viability in RH18 cells (77.3%,±5.44 and 60.9%±9.83 on
day 1; 20.9%±2.05 and 18.2%±18.74 on day 2; o1%±0 and
o1%±0 on day3) (Figure 3B).
ERMS and ARMS cell lines, RD2 and RH30, respectively, with
mutated p53 were used as negative controls. MTT showed minimal
changes in cell viability at both concentrations. RD2 cells treated
for 1, 2, and 3 days continued to proliferate with 5 and 10mM
of MI-63 treatments (88.5%±0.42 and 96.3%±18.03 on day 1;
96.3%±3.82 and 98.4%±23.48 on day 2; 90%±1.13 and
97.3%±18.38 on day3) (Figure 3C). Further, RH30 cells treated
with MI-63 also showed similar results (97%±10.59 and
107.4%±5.20 on day 1; 91.8%±11.81 and 107.5%±17.64 on day
2; 84.3%±24.88 and 100.4%±17.18 on day3) (Figure 3D).
The baseline levels of p53 and MDM2 were assessed in RH18 and
RH36 cells with wild-type p53 and in RH30 and RD2 cells
expressing mutant p53, which have higher levels of p53 (Figure 4).
The half-life of p53 in wild-type cells is short (Cinelli et al, 1998).
This is in part due to the role of MDM2 as an E3 ubiquitin ligase,
mediating a proteasomal degradation of p53 (Honda et al, 1997;
Fuchs et al, 1998). The degradation of the p53 protein by MDM2 is
inhibited in RH36 cells after treatment with MI-63, resulting in an
increased p53 half-life (Figure 5). Both wild-type p53-expressing
cell lines were treated with 10mM of MI-63. Western blot analysis
indicated an induction of p53. RH36 cells were treated for 20, 30,
and 40h. Although baseline levels of p53 were present in the
non-treated cells, levels increased after treatment. Antibodies for
p21
WAF1 were strongly positive when compared with those with no
treatment (Figure 6A). The apoptotic pathway was reactivated,
displayed by the increased presence of Bax protein by 30h after
HCT-116
p53 –/– & p53 +/+
HCT-116
p53 –/– & p53 +/+
No treatment
No treatment
10 uM Ml-63
10 uM Ml-63
p53
p21waf1
Cleaved caspase-3
Cleaved PARP
No Tx
p53 –/–
p53 +/+
No Tx
p53 –/–
p53 +/+
No Tx
p53 –/–
p53 +/+
No Tx
p53 –/–
p53 +/+
100
120
140
60
80
20
40
0
5uM MI-63 10uM MI-63 5uM MI-63 10uM MI-63
p53 –/–
GAPDH
Day 2 Day 3
p53 +/+
Figure 2 MI-63 treatments of HCT-116 p53 þ/þ and HCT-116 p53  /  cells. (A) MTT analysis indicates decreased cell proliferation with MI-63 in
cells with wild-type p53. (B) A measure of 50mg of total protein from HCT-116 cell lysates was subjected to SDS polyacrylamide gel electrophoresis
(PAGE) and transferred to PVDF membrane. Membranes were blotted with p53, p21
WAF1, cleaved caspase-3, and GAPDH antibodies.
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streatment, and by the presence of both cleaved caspase-3 and
cleaved PARP. RH18 cells expressing wild-type p53 were treated
for 24 and 36h and the findings were comparable (Figure 6B). p53
proteins increased from baseline with exposure to MI-63.
Induction of the p21
WAF1 protein was evident. Baseline levels of
Bax protein were unchanged; however, downstream apoptosis
proteins, cleaved caspase-3, and cleaved PARP were increased by
36h (Figure 6B). In contrast, western blot analyses of both RD2
and RH30 cells expressing mutated p53 treated with MI-63 showed
no change from untreated cells when p53, p21
WAF1, Bax, cleaved
caspase-3, and cleaved PARP proteins were evaluated (Figures 6C
and D). These results indicate that MI-63 selectively induces
apoptosis in rhabdomysarcoma cells expressing wild-type p53 but
not in rhabdomysarcoma cells expressing mutated p53.
MI-63 does not induce apoptosis in normal human muscle
cells (HSMM)
Normal human skeletal muscle cells, HSMM, were incubated for 2
and 3 days with 5 and 10mM MI-63. Cell viability was maintained
despite the treatment with 5 and 10mM MI-63 using MTT analysis
(114%±17.1 and 109.1%±21.3 on day 2; 105.4%±4.8 and
107.2%±7.3 on day 3) (Figure 7A). Western blots showed a
minimal presence of p53 and the downstream p21
WAF1 protein
after treatment with 10mM; however, there was no evidence of
apoptosis, as no cleaved caspase-3 or cleaved PARP was identified
in the SkBM-2 (Figure 7B) or DMEM (Figure 7C) medium.
MI-63 is a more potent MDM2 inhibitor than Nutlin-3
MI-63 has been shown to have a greater binding affinity for MDM2
and to have a greater effect on cell viability than Nutlin-3 (Ding
et al, 2006). Rh36 cells expressing wild-type p53 were incubated
with either MI-63 or Nutlin-3, an MDM2 inhibitor, for 3 days. MTT
assay showed a greater decrease in cell proliferation/viability by
MI-63 as compared with a similar concentration of Nutlin-3
(Figure 8). The IC50 values obtained for MI-63 and Nutlin-3 were
0.58mM and 1.35mM, respectively.
Quantitative combination effects between MI-63 and
doxorubicin
Incubation of RH-36 cells with either doxorubicin or MI-63 at
concentrations ranging from 12.5 to 200nM or from 1250 to
40000nM, respectively, led to a dose-dependent decrease of cellular
viability as determined by the MTT assay (Figures 9A and B). IC50
values obtained at 1, 3, and 5 days after treatment were 8416, 82,
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RH36 - Embryonal
wt p53
100
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80
Day 1 Day 2 Day 3
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Figure 3 The effect of MI-63 on the cell viability of ERMS/ARMS cells. (A, B) Rhabdomyosarcoma cells with wild-type p53, RH36 and RH18, showing
decreased cell proliferation when treated with MI-63. (C, D) Rhabdomyosarcoma cells with mutated p53, RD2 and RH30, showing decreased cell
proliferation when treated with MI-63.
MDM2
RH18 RH36 RH30
p53
GAPDH
RD2
Figure 4 Baseline levels of MDM2 and p53 expression in wild-type p53,
RH18 and RH36, and mutant p53, RH30 and RD2, rhabdomyosarcoma
cells.
DMSO 5M MI-63
0 60 120 0 60 Minutes
p53
GAPDH
120
Figure 5 The effect of MI-63 on p53 half-life in RH36 cells. Blocking
MDM2 activity inhibits p53 degradation resulting in an increased p53
half-life.
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sand 34nM for doxorubicin, and 576980, 5915, and 2407nM for
MI-63, respectively. MI-63 dosages of 420mM were saturated and
no further decrease in viability was observed (data not shown); this
may explain the exceptionally large IC50 values after 1 day of
treatment. To determine the combinational effects of these two
compounds, a constant molar ratio of 1:100, doxorubicin:MI-63,
was used at all time points studied of the individual drugs
(Figure 9C). A representative CI-effect plot for each time point is
presented (Figure 9D). All concentrations at each time point tested
have a CI value less than 1, indicating a synergism between
doxorubicin and MI-63. At day 5, CI values approach 1, possibly
indicating an additive effect; however, it must be noted that there
was a nearly complete cell kill by day 5 in many of the
concentrations. Overall, these data demonstrate a synergistic effect
between doxorubicin and MI-63 that could prove useful in therapy
to both improve survival and decrease toxicity.
DISCUSSION
Inhibition of p53 by MDM2 is known to have a role in tumour cell
proliferation and in increasing oncogenesis. Recent studies have
shown that targeted therapy directed at the p53–MDM2 interac-
tion may have a therapeutic benefit (Ding et al, 2006; Tovar et al,
2006). In this experiment, we demonstrate that a novel small-
molecule inhibitor, MI-63, has the ability to reactivate the
wild-type p53 function in paediatric RMS. MI-63 targets the
p53–MDM2 interaction, blocking the inhibition of the tumour
suppressor and protein ubiquitination (Ding et al, 2006). After
treatment, reactivation of wild-type p53 allows for downstream
cell-cycle arrest and initiation of apoptosis in both ARMS and
ERMS cell lines. Testing indicates that MI-63 has a minimal
apoptotic effect on normal human tissue in vitro.
p53 is a tumour suppressor gene that regulates cell cycle, DNA
repair, and apoptosis. Although specific mutations of the p53
protein have been described in approximately 50% of human
cancers, a disruption of wild-type p53 transcriptional activity can
independently contribute to tumourgenesis in other cancer types
(Chene, 2004; Haupt and Haupt, 2004; Tovar et al, 2006). MDM2 is
a regulator of p53 transcription activity. A direct binding to the
p53 transcription activation domain inhibits G1 cell-cycle arrest
and apoptosis signalling; however, with cellular stress, p53 activity
is enhanced and appropriate signalling occurs (Chen et al, 1996).
Increased activity of MDM2 contributes to defective, wild-type p53
regulation and can interrupt normal tumour suppressor activity,
leading to malignant proliferation (Chen et al, 1996; Keleti et al,
1996).
There have been several reports of MDM2 amplification and/or
overexpression in human cancers (Keleti et al, 1996; Momand et al,
1998; Klein and Vassilev, 2004; Takahashi et al, 2004; Levav-Cohen
et al, 2005; Tovar et al, 2006). Momand et al examined nearly 4000
tumour samples and reported a 7% frequency of MDM2
amplification, with the highest observed in soft-tissue sarcomas
(20%). Evaluation of RMS specifically suggests that an increased
MDM2 activity is present in a sub-population of both human tissue
samples and in vitro cell lines contributing to wild-type p53
inactivity (Keleti et al, 1996; Taylor et al, 2000; Takahashi et al,
2004). There seems to be no relationship between MDM2
RH36 – wtp53 RD2 – Mutated p53
No treatment
MI-63 – 20 h
MI-63 – 30 h
MI-63 – 40 h
DMSO
p53 p53
(+) Control
DMSO
MI-63 - 5M
MI-63 – 10M
No treatment
p21waf1
Bax
Cleaved caspase 3
Cleaved PARP
p21waf1
Bax
Cleaved caspase 3
Cleaved PARP
GAPDH GAPDH
RH18 – wt p53 RH30 – Mutated p53
(+) Control
DMSO
MI-63 - 5M
MI-63 – 10M
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p21waf1
p53
p21waf1
p53
Nto treatment
MI-63 – 24 h
MI-63 – 36 h
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Bax
Cleaved caspase 3
Cleaved PARP
GAPDH
Bax
Cleaved caspase 3
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Figure 6 Western blot analysis of ERMS/ARMS cells treated with MI-63. (A, B) Rhabdomyosarcoma cells with wild-type p53, RH36 and RH18, indicate
increased p53, downstream targets, p21
WAF1 and Bax, as well as cleaved caspase-3 and cleaved PARP, at 20, 30, and 40h after treatment with 10mM of MI-
63. (C, D) Rhabdomyosarcoma cells with mutated p53, RD2 and RH30, indicate no increase of p53, downstream target p21
WAF1, cleaved caspase-3, and
cleaved PARP at 24 and 36h after treatment with 10mM of MI-63.
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samplification and p53 mutation, suggesting that MDM2 provides
an alternative mechanism for inhibiting wild-type p53 (Keleti et al,
1996). Further, Taylor et al demonstrated the presence of wild-type
p53 in 19 of 20 ERMS and ARMS tissue samples obtained either at
the time of diagnosis or after chemotherapy. These findings draw
attention to the p53–MDM2 interaction in RMS, suggesting that
blocking MDM2 will reactivate wild-type p53.
The novel small-molecule inhibitor, MI-63, shows potential as
an MDM2 antagonist. The potent, non-peptide inhibitor of the
p53–MDM2 interaction is designed to mimic previously described
hydrophobic residues (Phe19, Trp23, and Leu26), and a newly
identified fourth residue (Leu22) in p53 that interacts with the
hydrophobic cleft on MDM2 (Ding et al, 2006). With this novel
design, MI-63 shows an increased binding (Ki 3n M) to MDM2, and
when compared with previously described non-peptide inhibitors
(i.e., Nutlin-3), MI-63 is approximately 12 times more potent (Ding
et al, 2006). Ding et al described a specific binding to MDM2, an
increase in p53 levels, and the increase of downstream target
p21
WAF1 in adult prostate cancer cells (LNCAP) after treatment.
The effect of MI-63 has also been observed in non-Hodgkin’s
lymphoma cell lines, in which similar results have been reported
(Jones et al, 2008). Our experiment is the first to specifically
analyse MI-63 and paediatric RMS (ERMS and ARMS) with wild-
type p53.
The results demonstrate the effectiveness of MI-63 against RMS
cell lines with wild-type p53. As hypothesised, both ERMS and
ARMS cells (RH36 and RH18, respectively) had decreased cell
viability after treatment. A previous evaluation of MI-63 demon-
strated a reactivation of p53, but only described downstream
increases in p21
WAF1. We looked at both cell growth arrest
and downstream indicators of apoptosis in ERMS and ARMS.
Expectedly, p53 and p21
WAF1 were elevated on western blot
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Figure 7 MI-63 treatments of HSMM cells. (A) MTT analysis shows minimal changes in cell proliferation when normal human skeletal muscle cells
(HSMM) are treated with MI-63. (B) Western blot analysis of HSMM cells grown in SkBM-2 medium with growth factors. (C) Western blot analysis of
HSMM cells grown in DMEM supplemented with 10% FBS. A measure of 50mg of total protein from HSMM cell lysates was subjected to SDS PAGE and
transferred to PVDF membrane. Membranes were blotted with p53, p21
WAF1, Bax, cleaved caspase-3, cleaved PARP, and GAPDH antibodies. The results
show an increase in p53 protein and p21
WAF1 at higher doses and prolonged exposure; however, there is no apparent reactivation of apoptosis.
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Figure 8 A comparison of the effects of MI-63 and Nutlin-3 on the
viability of RH36 cells. Treatment with MI-63 results in a greater decrease in
cell proliferation/viability.
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sanalysis. Pro-apoptotic markers, Bax, cleaved PARP, and cleaved
caspase-3, all increased after treatment with MI-63 and may
indicate a more comprehensive reactivation of p53. Notably,
human cell lines treated similarly had minimal increases in p53
and p21
WAF1 at higher doses of MI63; however, there was no
evidence of decreased cell viability or apoptosis. Blocking MDM2
in normal cells understandably leads to a reflexive increase in p53,
but importantly, this mechanism did not induce death. In vivo
studies and phase I trials will better describe the short- and long-
term effects of MI-63.
When treating RMS cells with MI-63 in combination with a
known chemotherapeutic agent, doxorubicin, synergism was
confirmed. Doxorubicin binds and intercalates DNA, inhibiting
macromolecular synthesis by blocking the action of DNA
topoismerase II. In addition, an inhibition of topoisomerase II
prevents replication. As doxorubicin may act in a p53-independent
manner, we hypothesised that a combination treatment with MI-63
would potentiate each drug’s anti-proliferative effects (Taylor et al,
2000). The data agree with this supposition, most noted at early
time points. Specifically, 20nM of doxorubicin, in combination
with 2000nM MI-63 (day 1), showed a 49% increase in the fraction
of cells affected by treatment when compared with the expected
additive effect. In vivo studies, as well as clinical trials, are
necessary to fully evaluate combinatorial effects and clinical usage.
In summary, we have shown that the novel small-molecule
inhibitor, MI-63, successfully blocks MDM2 and reactivates p53
and downstream cell signalling when tested in vitro. Further,
antitumour effects occur with minimal toxicity to normal cells and
show synergism when combined with a known chemotherapeutic
agent, doxorubicin. In vivo studies on the therapeutic potential of
MI-63 are needed. Moving forward, as both RMS and other solid
tumours (i.e., neuroblastoma) have wild-type p53 protein, clinical
trials may focus on blocking p53–MDM2 interaction in solid
tumours as a whole.
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